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Summary Prodrugs are pharmacologically inactive chemical derivatives of a drug molecule that 
require a transformation within the body in order to release the active drug. They are 
designed to overcome pharmaceutical and/or pharmacokinetically based problems asso-
ciated with the parent drug molecule that would otherwise limit the clinical usefulness of 
the drug. 
The scientific rationale, based on clinical pharmaceutical and chemical experience, 
for the design of various currently used prodrugs is presented in this review. The examples 
presented are by no means comprehensive, but are representative of the different ways in 
which the prodrug approach has been used to enhance the clinical efficacy of various drug 
molecules. 
The term 'prodrug' is used to describe com-
pounds which must undergo chemical transform-
ation within the body prior to exerting their 
pharmacological or therapeutic action. The term 
'prodrug' or 'proagenf was first used by Albert 
(1958) who suggested that this approach could be 
used to alter the properties of drugs, in a temporary 
manner, to increase their usefulness, and/or to de-
crease associated toxicity. 
7. The Prodrug Concept 
The prodrug concept is illustrated in figure 1. A 
drug whose usefulness is limited by adverse phys-
icochemical properties, such that it is not capable 
of overcoming a particular barrier, is chemically 
modified via the attachment of a promoiety to gen-
erate a new chemical entity, the prodrug, whose 
properties are such that it is capable of traversing 
the limiting barrier. Ideally, the promoiety/drug 
bond will be designed to be cleaved efficiently by 
enzymatic or non-enzymatic means (Kupchan et 
al.? 1965), followed by the subsequent rapid elim-
ination of the released promoiety. 
The term 'drug latentiation' has also been ap-
plied to this concept. Harper (1959, 1962) de-
scribed drug latentiation as the chemical modifi-
cation of a biologically active agent to form a new 
compound which upon in vivo enzymatic attack will 
liberate the parent compound. The chemical alter-
ation of the parent compound is such that the 
change in physicochemical properties will affect the 
absorption, distribution and enzymatic metabol-
ism. Such compounds have also been called bio-
reversible derivatives and congeners, but 'prodrug' 
is now the most commonly accepted term (Higuchi 
and Stella, 1975; Roche, 1977a; Sinkula and Yal-
kowsky, 1975). 
Clinically relevant prodrugs are abundant. Many 
of the drugs that were developed as early as the 
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late nineteenth century are in fact prodrugs: for ex-
ample, hexamine (methenamine) and aspirin are 
prodrugs of formaldehyde and salicylic acid, re-
spectively. Aspirin is less corrosive than salicylic 
acid to the gastrointestinal mucosa and quantita-
tively releases salicylic acid in vivo by the action 
of esterases. Formaldehyde, as a contact antibac-
terial, could not be used as a urinary tract antisep-
tic until it was formulated as an enteric-coated tab-
let of hexamine. After absorption, hexamine is 
excreted in the urine, which if acidified, provides 
a medium in which formaldehyde is generated. 
Here the problem overcome was one of transport 
limitation, and site-specific delivery was achieved. 
Barrier 
to drug's 
usefulness 
D r u g 
Non-toxic 
and rapidly 
excreted 
F i g . 1. Schematic representation of the 'prodrug' concept 
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2. Barriers to Drug Development 
In figure 1, the term 'barrier' is used rather 
loosely. It is easy to envisage a true biological bar-
rier, such as the blood-brain barrier, when dis-
cussing the problems of drug delivery to the central 
nervous system (CNS). However, there are various 
other barriers that are not always recognised by end-
users of a drug product that must be resolved be-
fore a new chemical entity can become a useful 
drug. Aliens and Simonis (1974) described the pro-
cess of drug development as occurring in three 
phases: the pharmaceutical, pharmacokinetic, and 
pharmacodynamic phases. The pharmacodynamic 
phase, which involves the drug/receptor interac-
tion, is not a phase where prodrugs are usually con-
sidered to act, although Bey (1978) has suggested 
that suicide substrates or K c a t inhibitors (com-
pounds containing latent reactive groupings which 
are specifically unmasked by the action of target 
enzymes) can be considered as prodrugs. 
2.1 Pharmaceutical Phase 
The pharmaceutical phase can be considered as 
the phase of development which occurs between 
the identification of a new chemical entity with 
measured or proposed therapeutic potential and its 
incorporation into a drug delivery system. The de-
livery system may be one of the traditional forms 
such as tablets, capsules, injections, creams/oint-
ments etc., or one of the new drug delivery modes, 
e.g. transdermal delivery patches or implanted de-
vices. Two barriers in this phase to the develop-
ment of a commercially usable drug product are: 
1. The aesthetic properties of the new molecule 
may limit its usefulness, e.g. odour, taste, pain 
upon injection, gastrointestinal irritability, etc. 
2. Formulation problems may become apparent, 
e.g. the drug is unstable, or because of its phys-
icochemical properties, cannot be incorporated 
into a particular type of dosage form. 
2.2 Pharmacokinetic Phase 
The pharmacokinetic phase can be considered 
as that phase involving the study of the absorption, 
distribution, metabolism and excretion of the drug. 
These studies provide valuable information about 
the in vivo properties of a drug's limitations such 
as poor absorption, too rapid elimination, and pre-
systemic metabolism. If these properties can be re-
lated back to the physicochemical and dosage form 
properties of the system, then correction can be 
made. Occasionally, these corrections will require 
prodrug interventions. 
The principal barriers identified in the phar-
macokinetic phase are: 
1. Incomplete absorption of the drug from the de-
livery system or across biological barriers such 
as the gastrointestinal mucosal cells and the 
blood-brain barrier 
2. Too rapid or too slow transport of the drug to 
the body, i.e. the rate of drug action onset needs 
to be optimised 
3. Incomplete systemic delivery of an agent due to 
presystemic metabolism in the gastrointestinal 
lumen, mucosal cells, and liver 
4. Toxicity problems associated with local irrita-
tion or distribution into tissues other than the 
desired target organ 
5. Poor site specificity of the drug. 
There are numerous clinical examples and lit-
erature references on the use of prodrugs attempt-
ing to solve the problems mentioned above. Many 
of these examples have appeared in comprehensive 
reviews (see table I). Some of the clinically or po-
tentially clinically relevant examples, as well as 
some of the problems associated with the use of 
prodrugs, are presented in this article. The reviews 
listed in table I should be consulted for extensive 
coverage of the subject. 
3. Use of Prodrugs to Overcome 
Pharmaceutical Barriers 
The formulation of a new chemical entity with 
suspected therapeutic benefits requires that the drug 
be formulated into a delivery form that is chemi-
cally stable, free from taste and odour problems 
(particularly if it is for paediatric use or intended 
for parenteral administration), and the drug/form-
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Table I. Comprehensive review articles on prodrugs 
ulation must be relatively free of irritation on 
administration. For intravenous usage, the drug 
should have adequate water solubility and remain 
in solution for sufficient time to permit adminis-
tration of the complete dose. 
3.1 Masking Taste or Odour Problems 
Chloramphenicol is an extremely bitter sub-
stance inhibiting its usage in paediatric formula-
tions. Chloramphenicol palmitate, a sparingly so-
luble ester of chloramphenicol, is practically 
tasteless because of its low aqueous solubility 
(Glazko et al., 1952). Since the interaction of a drug 
or prodrug with taste receptors requires the drug 
to be sufficiently soluble in saliva, by lowering the 
aqueous solubility to mask a taste problem, one 
runs the risk of creating a more serious problem, 
i.e. incomplete dissolution of the prodrug in the 
gastrointestinal tract, resulting in incomplete ab-
sorption. However, the commercially used form of 
cloramphenicol palmitate is efficiently hydrolysed 
to active chloramphenicol by the action of pan-
creatic lipase on solid chloramphenicol palmitate 
particles (Andersgaard et al., 1974). Interestingly, 
other polymorphs - different crystalline forms of 
chloramphenicol palmitate - which are also taste-
less, do not provide good plasma concentrations of 
chloramphenicol because of poor solubility and the 
fact that the solid-to-solution transition is not ca-
talysed by lipase. Other examples of the use of pro-
drugs to mask taste are listed in table II. 
Odour is another aesthetic concern for some 
drugs. Such compounds are often volatile liquids, 
or solids with significant vapour pressure that 
makes them difficult to formulate. A classic ex-
ample of this are the volatile mercaptans used as 
tuberculostatic agents and for the treatment of lep-
rosy. Ethyl mercaptan has a boiling point of 25°C 
and a strong disagreeable odour. Diethyldithioiso-
phthalate, a prodrug of ethylmercaptan, has a 
higher boiling point, is relatively odourless (Davies 
et al, 1956; Davies and Driver, 1957) and has been 
used topically (as an enunction) for the systemic 
delivery of ethylmercaptan which is generated from 
the prodrug by the action of systemic thioesterases. 
3.2 Reduction of Pain or Irritation at 
Injection Sites 
Pain or irritation at an injection site may be 
caused by precipitation of the drug, by cell lysis 
due to either hypo- or hyperosmotic solutions, the 
properties of the drug itself, or the corrosive action 
of the drug at nerve endings. Some of these prob-
Selective toxicity 
Molecular pharmacology as a basis 
for drug design 
Modulation of pharmacokinetics by 
molecular modulation 
Novel approaches in prodrug design 
Novel bioreversible derivatives of 
amides, imides, ureides, amines and 
other chemical entities not readily 
derivatisable 
Drug latentiation 
Prodrugs as novel drug delivery 
systems 
Prodrug design 
Design of biopharmaceutical 
properties through prodrugs and 
analogues 
Rationale for design of biologically 
reversible drug derivatives 
Prodrug approach in drug design 
Chemical modification of drugs to 
overcome pharmaceutical problems 
Albert (1973) 
Ariens (1966) 
Ariens (1971) 
Bodor (1982) 
Bundgaard (1982) 
Digenis and 
Swintosky (1975); 
Harper (1959, 1962) 
Higuchi and Stella 
(1975) 
Notari (1981) 
Roche (1977a) 
Sinkula and 
Yalkowsky (1975) 
Sinkula (1975) 
Stella (1973) 
Drug substances in particular 
prodrugs: problems and methods 
or approaches 
Prodrugs and site specific delivery 
A physical chemical basis for the 
design of orally active prodrugs 
Stella (1977) 
Stella and 
Himmelstein (1980) 
Yalkowsky and 
Morozowich (1980) 
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Table II. Some examples of prodrugs designed to mask taste 
problems 
Drug Prodrug Reference 
Chloramphenicol Palmitate 
Clindamycin Palmitate 
Erythromycin 
Oleandamycin 
•neomycin 
Sutphafurazole 
(sulfisoxazole) 
Dextro-
propoxyphene 
Ethy! succinate 
Ethyl carbonate 
Acyl ester and 
N-oxide 
Phosphate ester 
Carbonate ester 
N'-Acetyl 
Napsylate 3 
Glazko et al. (1952) 
Sinkula et al. (1973) 
Murphy (1953) 
Clark and Varner 
(1957) 
Celmer (1968) 
Morozowich et al. 
(1969, 1973) 
Sinkula and Lewis 
(1973) 
McEvoy (1974) 
Gruber et al. (1971) 
a Sparingly soluble salt. 
Note: In the case of salts, the promoiety/drug linkage is ionic, 
and not covalent. However, these specialised salts can still be 
called prodrugs (Stella, 1975). 
lems may relate to the vehicle composition or ve-
hicle pH needed for formulation purposes. 
Clindamycin hydrochloride, an antibiotic with 
an aqueous solubility of 3 mg/ml, produces a great 
deal of pain upon intramuscular injection, while 
clindamycin 2-phosphate, a prodrug of clindamy-
cin with a solubility of > 150 mg/ml, does not cause 
irritation or pain upon intramuscular administra-
tion (Edmondson, 1973; Gray et al., 1974). The 
prodrug has no intrinsic antibacterial activity and 
is converted to clindamycin in vivo with a half-life 
of approximately 10 minutes by the action of phos-
phatase enzymes (DeHaan et a l , 1973). Figure 2 
shows serum concentrations of clindamycin 2-
phosphate and free clindamycin versus time after 
a 20mg intravenous infusion (10 min) of clinda-
mycin 2-phosphate. Although the phosphate ester 
is detected in the serum for a substantial length of 
time, most of it is ultimately cleaved to clinda-
mycin, with only 1 to 2% of the dose appearing as 
unchanged prodrug in the urine (DeHaan et al., 
1973). The clinical advantage here is that an intra-
muscular clindamycin preparation may not have 
been commercially viable without the develop-
ment of the phosphate prodrug. 
A further example is provided by the anticon-
vulsant drug phenytoin (5,5-diphenylhydantoin) 
which is formulated for intravenous or intramus-
cular use in 40% propylene glycol, 10% alcohol and 
50% water with the pH adjusted to « 12. At this 
pH, phenytoin is present in its anionic form (sod-
ium phenytoin). These formulation conditions are 
necessary because phenytoin has an aqueous so-
lubility of only 0.02 mg/ml and is weakly acidic 
(pK a 8.3). Therefore, a high pH and the presence 
of cosolvents are necessary to provide a 50 mg/ml 
F i g . 2 . Mean serum concentration (mg/L) of clindamycin • ) 
and clindamycin 2-phosphate (as clindamycin equivalent) 
(O O) after a 20mg intravenous infusion of clindamycin 
phosphate over a 10-minute period (after DeHaan et al., 1973). 
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sodium phenytoin injection preparation suitable for 
intravenous or intramuscular usage. However, this 
formulation is very toxic after rapid intravenous 
injection due to possible precipitation of phenytoin 
in the vein as the pH adjusts to the physiological 
value of 7.4, and due to the fact that propylene 
glycol is a cardiac depressant (Atkinson and Dav-
ison, 1974). Similarly, on intramuscular injection, 
phenytoin precipitates at the injection site. Re-
cently, Varia et al. (1984a,b,c,d) evaluated a series 
of prodrugs of phenytoin that have superior solu-
bility and potential therapeutic benefits over the 
current sodium phenytoin injectable form. The di-
sodium salt of the phosphate ester of 3-hydroxy-
methylphenytoin was found to be pharmacologi-
cally inert, generated phenytoin rapidly and 
quantitatively in vivo in rats and dogs, and on 
intramuscular administration gave no apparent ir-
ritation while rapidly releasing phenytoin. This 
prodrug is currently undergoing evaluation as a 
possible alternative to the use of sodium pheny-
toin. 
Steroids are another group of compounds hav-
ing poor water solubility. Glucocorticoids such as 
betamethasone, prednisolone, methylprednisolone, 
hydrocortisone and dexamethasone are available 
as water-soluble disodium phosphate or sodium 
succinate prodrugs. The sodium succinate forms 
are available only as lyophilised powders for re-
constitution because of their relatively poor chem-
ical stability compared with the phosphate esters. 
The lyophilisation is also an expensive process. 
Ideally, when a prodrug is used to improve 
aqueous solubility to allow intravenous adminis-
tration of a drug, it should be rapidly and quan-
titatively hydrolysed in the body, and it should also 
have no intrinsic therapeutic activity or toxicity. If 
a very water-soluble prodrug is not rapidly con-
verted to the parent drug after administration, it 
may be significantly eliminated in the urine thereby 
reducing drug bioavailability. The possibility of 
prodrug accumulation in the body, particularly in 
patients with impaired renal function, may also be 
a problem. Studies with chloramphenicol sodium 
3.3 Alteration of Drug Solubility 
The prodrug approach can be used to increase 
or decrease the solubility of a drug depending on 
its ultimate use. One advantage of making a less 
soluble prodrug (to mask taste) and the possible 
problems it can create - i.e. compromised bio-
availability - has already been discussed (section 
3.1). There are numerous examples where solubil-
ity needs to be increased. The prime examples in-
volve drugs whose solubility is so low that a so-
lution dosage form for intravenous usage is not 
possible. 
3.3.1 Chloramphenicol and Corticosteroids 
Whereas the palmitate ester of chloramphenicol 
has proved useful for oral formulations, a more 
water-soluble form, chloramphenicol sodium suc-
cinate, has been developed for parenteral admin-
istration (Glazko et al, 1957). Chloramphenicol 
sodium succinate has no antibacterial activity but 
is hydrolysed in the body to free chloramphenicol 
by the action of esterases. 
Table III. Plasma Cortisol AUCo-240 values after intravenous and 
intramuscular injections of hydrocortisone sodium succinate and 
hydrocortisone disodium phosphate in humans (after Melby and 
St Cyr, 1961) 
Prodrug3 Route of 
adminis-
tration 
Plasma 
Cortisol 
AUCo-240 
(mg/L- min) 
Hydrocortisone sodium IV 
succinate 
Hydrocortisone disodium IV 
phosphate 
Hydrocortisone sodium 1M 
succinate 
Hydrocortisone disodium IM 
phosphate 
1.42 X 1 0 4 
2.12 X 1 0 4 
1.55 X 1 0 4 
2.18 x 1 0 4 
a Both prodrugs have essentially the same molecular weight , 
so even though the dose administered (1 mg/kg) w a s o n a 
weight basis, comparison of AUCs is possible. 
Abbreviations: A U C 0 . 2 4 o a r e a under the plasma concentration-
time curve over 240 minutes; IV = intravenous; IM = intramus-
cular. 
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succinate have shown that 30 to 40% of the pro-
drug is excreted in the urine as such (Nahata and 
Powell, 1981), thus complicating chloramphenicol 
therapy. 
There are similar indications that the succinate 
esters of corticosteroids (Melby and St Cyr, 1961) 
are incompletely broken down to the parent ster-
oid. Melby and St Cyr (1961) compared plasma 
concentrations of hydrocortisone, prednisolone and 
dexamethasone after intravenous and intramus-
cular administration of the phosphate and succi-
nate esters. The areas under the 0 to 240 minute 
plasma concentration-time curves (AUCs) [table 
III] clearly demonstrate that the hydrocortisone was 
more efficiently released from the phosphate ester 
(disodium salt). The rapid hydrolysis of the phos-
phate esters can probably be attributed to the 
abundance of phosphatase enzymes, while the 
poorer performance of the succinate esters, i.e. their 
inability to be rapidly and quantitatively cleaved 
by esterases, may be due to the presence of an an-
ionic site (the free carboxylate) near the ester bond 
(Krish, 1971). 
Table !V. Aqueous solubilities of various phenytoin prodrugs 
(derivatives of 3-hydroxymethylphenytoin) relative to phenytoin 
Prodrug Relative 
( - R ) solubility 
(phenytoin ~ 1) 
—COCH2NH+(CH3)2 • CH3CO3" 8810 
—CO(CH 2 ) 2 NH + (C 2 H 5 ) 2 - napsylate 39 
—COO(CH 2) 2NH +(CH 3) 2 • CH3SO3- 4730 
— P 0 3 2 - N a 2 + 4500 
3.3.2 Phenytoin 
As discussed above (section 3.2), some water-
soluble prodrugs of phenytoin have recently been 
developed (Varia et al, 1984a,b,c,d). Phenytoin has 
a high melting point indicating strong crystal lat-
tice energy, which on dissolution is not compen-
sated for by the release of solvation forces. There-
fore, phenytoin is very water-insoluble and can only 
be dissolved at a high pH, as sodium phenytoin, 
and with the help of cosolvents. We have found 
that phenytoin reacts with an excess of formalde-
hyde to produce 3-hydroxymethylphenytoin which 
can be further derivatised to give the water-soluble 
prodrugs listed in table IV. 
Dramatic increases in aqueous solubility are seen 
with the disodium phosphate ester, which has also 
been determined to be the most desirable pheny-
toin prodrug based on chemical stability, as well 
as in vivo performance (Varia and Stella, 1984c,d). 
Upon cleavage of the phosphate group, the 3-hy-
droxymethyl derivative is formed, which in the 
absence of formaldehyde rapidly looses formalde-
hyde (t./2 < 2 sec at 37°C and pH 7.4) to generate 
phenytoin. Table V illustrates the advantages of this 
phosphate ester in delivering phenytoin after intra-
muscular administration of the prodrug to rats in 
comparison with sodium phenytoin. The lower 
phenytoin concentrations from sodium phenytoin 
are probably the result of phenytoin precipitation 
after the cosolvent is diluted and the pH has ad-
justed to physiological pH. The higher phenytoin 
concentrations from the prodrug reflect its rapid 
release from the intramuscular site and subsequent 
in vivo cleavage to phenytoin. 
This solution to the phenytoin problem raises 
an interesting question: does the formaldehyde 
produced cause toxicity? As with any prodrug so-
lution to a problem, the prodrug itself and its de-
composition product must be safe, or at least should 
not add to possible toxicity. Although in theory the 
formaldehyde produced by the 3-hydroxymethyl-
phenytoin could be toxic, in practice the prodrug 
will only be used in acute cases where the patient, 
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Table V. The relative areas under the blood concentration-time curves over 210 minutes (AUC 0- 2io) and maximum blood concen-
trations of phenytoin after a 10 mg/kg intramuscular dose of sodium phenytoin and a 7 mg/kg intramuscular phenytoin equivalent 
dose of its phosphate prodrug to rats (± SD) 
Compound Dose a 
(mg/kg) 
Maximum blood 
concentration 
(mg/L) 
(min) 
AUCo~2io 
(mg/L - min) 
Sodium phenytoinb 10 1.05 (± 0.40) 30 97.8 ( ± 82.0) 
Phosphate prodrug0 7 2.95 (± 0.60) 45 339.8 ( ± 9.7) 
a Phenytoin equivalents. 
b In a 40% propylene glycol, 10% alcohof, 50% water vehicle (pH « 12). 
c In sterile distilled water. 
over a week, will receive less than 2g equivalents 
of phenytoin or approximately 200mg of formal-
dehyde, which would rapidly convert to CO2. Most 
drugs that undergo N- or O-demethylation produce 
larger quantities of formaldehyde than the 3-hy-
droxymethylphenytoin conversion, and many of 
these drugs are used clinically. Therefore, the 
amount of formaldehyde produced from this sys-
tem is not anticipated to cause any serious prob-
lems. 
3.3.3 Sulindac 
In contrast to parenteral dosage forms, there are 
surprisingly few examples of a clinically relevant 
nature where the prodrug approach has been used 
to increase aqueous solubility in order to improve 
the oral absorption of drugs. This can partly be 
traced to how drugs were screened for activity up 
until about 10 years ago. Screening usually in-
volved the oral and/or subcutaneous administra-
tion of the drug to rats or mice, and the measure-
ment of a pharmacological response. If the drug 
had poor aqueous solubility, it was often given as 
a suspension, so the only drugs which showed ac-
tivity were those with sufficient solubility or high 
intrinsic bioactivity to elicit a response. Thus, the 
screening procedures not only eliminated inactive 
drugs, but also those drugs with limited aqueous 
solubility. Those drugs which did give a response 
had some solubility in water. Therefore, when these 
compounds were formulated into tablets and the 
tablet formulation optimised for release character-
istics, they often performed fairly well. With the 
knowledge of how solubility can affect screening 
results, and the use of biochemically based screens, 
current analogue and prodrug approaches to solv-
ing solubility problems are becoming an integral 
part of the drug design process. An example of this 
is the recent development of the indene non-ster-
oidal anti-inflammatory agent sulindac as a pro-
drug of sulindac sulphide (Shen and Winter, 1977) 
[fig. 3]. Sulindac was developed primarily to re-
duce gastrointestinal toxicity (see also section 4.4.1) 
and is 100 times more water soluble than the sul-
phide. At pH 7.4, the solubility of sulindac is 3.3 
mg/ml while that of the sulphide is 0.03 mg/ml 
(Shen, personal communication). Because of this 
greater solubility and the fact that it still maintains 
sufficient lipophilicity for gastrointestinal absorp-
tion (octanol: water partition coefficient at p H 7.2 
is 1.52; Shen and Winter, 1977), sulindac is well 
absorbed after oral administration (Duggan et aL, 
1977). 
One should always remember that increased 
aqueous solubility does not necessarily result in 
improved bioavailability for dissolution rate-lim-
ited, poorly bioavailable drugs. Because of the lipo-
philic nature of most cell membranes, including 
those of the gastrointestinal mucosal cells, a proper 
balance between changes in aqueous solubility and 
drug lipophilicity must be maintained. This is dis-
cussed in greater detail in section 4.1. 
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3.4 Enhancement of Chemical Stability 
A very important requirement of all drug prod-
ucts is that they must be chemically stable over a 
reasonable period. Except for products like vac-
cines, some cytotoxic agents, and other life-saving 
products, a shelf-life of at least 2 years is desirable. 
If a drug is chemically very unstable and the in-
stability problem cannot be resolved by formula-
tion means, it is sometimes possible to develop a 
prodrug with enhanced stability over the parent 
drug. This usually takes the form of chemical mod-
ification of the functional group responsible for the 
instability, or a change in the physical properties 
of the drug (via prodrug modification) resulting in 
the reduction of contact between the drug and the 
media in which it is unstable. 
Aqueous sodium ampicillin is chemically very 
unstable in concentrated solution due to autoam-
inolysis, i.e. the side chain primary amino group 
of the ampicillin molecule is capable of attacking 
the jS-lactam ring of a second ampicillin molecule 
to give various polymeric species (Bundgaard, 1974; 
Stewart, 1967, 1968). Hetacillin is a prodrug of am-
picillin formed by its reaction with acetone. When 
hetacillin is diluted for intravenous infusion (< 20 
mg/ml ampicillin equivalents) it readily dissociates 
to ampicillin and acetone. However, in concen-
trated solutions, the hetacillin only partially dis-
sociates. Since the interaction of the side chain of 
ampicillin and acetone 'ties up' the amino group, 
hetacillin does not undergo the autoaminolysis re-
action and is a relatively stable prodrug form of 
ampicillin sodium (Schwartz and Hayton, 1972). 
In the body, hetacillin readily dissociates to pro-
duce ampicillin. 
As stated in the footnote to table II, salts of a 
drug may or may not be considered prodrugs, since 
the promoiety/drug linkage in this instance is ionic 
and not covalent. However, assuming that they are 
considered prodrugs (i.e. the properties of the new 
salt are unique), then the sparingly soluble ben-
zathine and procaine salts of penicillin G can be 
termed prodrugs. Penicillin G is very unstable in 
aqueous solution and it is not possible to formulate 
penicillin G as a stable aqueous solution. The rate 
of inactivation of drugs in solution usually follows 
pseudo first-order kinetics. The procaine and benz-
athine salts of penicillin have poor aqueous so-
lubility. When these salts are formulated as sus-
pensions, only the fraction of penicillin G in 
solution, given by its solubility product, will de-
grade, so these sparingly soluble salts give suspen-
sions of penicillin G quite long shelf lives. The 
napsylate salt of dextropropoxyphene also is more 
stable than the corresponding hydrochloride salt. 
F i g . 3 . Sulindac was specifically developed as the prodrug of sulindac sulphide. 
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4. Use of Prodrugs to Overcome 
Pharmacokinetic Barriers 
The absorption, distribution, metabolism and 
excretion of a drug are all dynamic processes that 
are affected by the physicochemical properties of 
the drug. Variations in bioavailability, for exam-
ple, can lead to variations in patient response to a 
drug, and in animals can lead to ambiguous inter-
pretation of the efficacy of the drug. 
4.1 Enhancement of Oral Absorption 
If a drug is very water insoluble, bioavailability 
after oral dosing is often dissolution rate limited. 
As stated above (section 3.3.3) there are only a few 
examples where prodrugs have been used to im-
prove drug absorption of dissolution rate-limited 
drugs. 
For agents that are highly polar in nature, it is 
often the transport of the drug across the gastroin-
testinal mucosal cell membranes that limits drug 
absorption. Since most drugs are absorbed by pas-
sive diffusion, a degree of lipophilicity is necessary 
for efficient absorption through the gastrointestinal 
barrier (Ho et a l , 1977). For highly polar com-
pounds, the administration of a less polar, more 
lipophilic prodrug may help promote gastrointes-
tinal absorption. This approach has been success-
fully applied with various penicillin derivatives. 
4JA Ampicillin 
Ampicillin is highly polar and at the pH of the 
gastrointestinal tract is mostly present in a zwit-
terionic form. Its bioavailability after oral dosing 
is only 20 to 60% (Bolme et al., 1976). A number 
of less polar prodrugs of ampicillin have been pre-
pared by esterifying the carboxyl group of ampi-
cillin. Those currently receiving the most attention 
are bacampicillin, pivampicillin and talampicillin 
(fig. 4). 
These ester prodrugs of ampicillin are efficiently 
absorbed and are cleaved by general esterase en-
zymes in the body, most often in the mucosal cells 
themselves, releasing ampicillin. In the case of bac-
ampicillin, the products of the cleavage are acet-
aldehyde, carbon dioxide and ethanol. For piv-
ampicillin, it is formaldehyde (see earlier discussion 
of the toxicity question, section 3.3.2) and pivalic 
acid. The bioavailability characteristics of all these 
prodrugs are significantly superior to ampicillin it-
self (Ehrnebo et al, 1979; Loo et al., 1974; Sjovall 
et al, 1978). Figure 5 shows ampicillin plasma con-
centrations versus time in human volunteers given 
equimolar amounts of bacampicillin and ampicil-
lin (Magni et al., 1976). There is an approximate 
2- to 5-fold increase in relative oral bioavailability 
when bacampicillin is administered. Bacterial in-
fections treated with drugs like ampicillin often re-
quire the drug to reach other tissues and organs, 
besides the plasma. Simon et al. (1978) demon-
strated that ampicillin tissue concentrations fol-
lowing bacampicillin administration correlated with 
the increased blood concentrations of ampicillin. 
For other examples where prodrugs have been 
developed to improve the gastrointestinal absorp-
tion of polar drugs, see Bodor (1977), Vickers et 
al. (1978), Roche (1977b) and Saari et al. (1978). 
4.2 Prevention of Presystemic Metabolism 
Many drugs are efficiently absorbed from the 
gastrointestinal tract but undergo presystemic me-
F i g . 4 . The ester prodrugs of ampicillin: bacampicillin, pivam-
picillin and talampicillin. 
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tabolism or inactivation before reaching the sys-
temic circulation. This inactivation may be chem-
ically or enzymatically based. The acid in the 
stomach, for example, partially degrades a number 
of drugs before they can be efficiently absorbed. 
The major problem associated with enzymatic me-
tabolism is that orally administered drugs are ex-
posed to the enzymes of the gastrointestinal lumen, 
the brush border, the mucosal cell and the liver, 
prior to reaching the systemic circulation. 
A major class of drugs that undergo marked pre-
systemic metabolism are those containing phenolic 
moieties. Sulphation, glucuronidation and, to a mi-
nor extent, methylation all contribute to rapid in-
activation of many of these drugs. For example, 
only 4% of orally administered isoprenaline (iso-
proterenol) reaches the systemic circulation intact 
as compared with an equivalent intravenous dose 
(Redwood, 1969). Similarly, conjugation of other 
phenolic molecules such as salicylamide, a-methyl-
dopa, terbutaline and salbutamol also limits their 
systemic availability. Presystemic metabolism is not 
just limited to drugs with phenolic moieties. Oxi-
dative N- and O-dealkylation, ester cleavage and 
peptide degradation are other major cleavage routes. 
However, the phenols, as a class of presystemically 
metabolised drugs, have been the most extensively 
studied with respect to developing suitable pro-
drugs for preventing their presystemic clearance. 
42.1 Traditional Prodrug Approaches with 
Phenolic Compounds (e.g. paracetamol) 
The traditional approach has been to 'mask the 
metabolisable moiety', i.e. to derivatise the phe-
nolic group with either an ester or ether type group. 
These approaches have met with only marginal 
success in preventing presystemic clearance of the 
parent drug. 
The basis for this poor performance can be seen 
in the work of Pang and Gillette (1978) who stud-
ied the liver metabolism of paracetamol (aceta-
minophen) and its prodrug, phenacetin (acetophe-
netidin), in an in vitro perfused liver study. The 
steady-state hepatic extraction ratio is the fraction 
of drug eliminated during its passage through the 
liver, and this was measured for both paracetamol 
Time (h) 
F i g . 5 . Mean serum concentration (mg/L) of ampicillin in human 
volunteers following oral administration of equimolar amounts 
of bacampicillin (400mg) [O O] and ampicillin (278mg) 
[ B • ] (after Magni et al., 1976). 
and phenacetin. It was found that the extraction 
ratio of paracetamol perfused as paracetamol was 
less than the extraction ratio of paracetamol per-
fused through the liver as phenacetin; i.e. paracet-
amol produced from phenacetin by the liver was 
more efficiently metabolised. This process was re-
ferred to by Pang and Gillette (1978) as sequential 
metabolism. Qualitatively, in this case the O-de-
alkylation of phenacetin to paracetamol occurs in 
the liver, and since the active drug (paracetamol) 
is metabolised by the same organ (the liver), it is 
rapidly inactivated by conjugation. Thus paracet-
amol is more efficiently metabolised when admin-
istered as the phenacetin prodrug. Therefore, de-
signing prodrugs to mask phenolic groups will not 
be successful in preventing presystemic metabol-
ism unless the 'demasking' occurs in an organ other 
than where the presystemic metabolism of the par-
ent drug occurs. This concept of sequential organ 
metabolism may explain the apparent failures seen 
with most postulated ester and ether prodrugs of 
phenols, since the liver and intestinal mucosal cells 
are rich in esterase and oxidative O-dealkylation 
(P-450) enzymes. 
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4.22 New Prodrug Approaches 
Future prodrug research for the prevention of 
presystemic metabolism of phenols may well fol-
low the outline shown in figure 6. This involves 
the design of firstly 'masking' promoieties which 
are not cleaved in the intestinal lumen, mucosal 
cell or liver, but by a systemic enzyme; thus, the 
functional group which is the source of the prob-
lem is protected. A second approach which we have 
been pursuing involves a biochemical technique 
(Williams, Pitman and Stella, unpublished data). 
Knowledge of the structure-reactivity requirements 
of a particular enzyme system (e.g. phenol sulpho-
transferase) allows one to recognise that the pro-
moiety could be placed at some other position in 
the drug molecule (fig. 6) such that the prodrug is 
no longer a substrate - due to either steric, elec-
tronic or other effects - for the presystemic me-
tabolising enzyme; i.e. even though the functional 
group originally attacked is not directly 'masked', 
the physicochemical properties of the prodrug are 
such that it is not recognised as a substrate. The 
advantage of this approach may well be the use of 
promoieties attached to other parts of the molecule 
that could not be easily placed on the phenolic 
group directly. However, the cleavage of the pro-
moiety should still be triggered after passage 
through the liver, otherwise sequential metabolism 
will occur. This approach will require input from 
biochemists and enzymologists to be successful. 
Fig. 6 . Probable future prodrug approaches for prevention of presystemic metabolism of phenolic compounds. T h e s e involve the 
design of either 'masking' promoieties which are cleared by a systemic enzyme rather than in the intestinal lumen, mucosal 
cell or liver, or a promoiety that is placed at some other position In the drug molecule[ -^h-] such that the prodrug i s no longer a 
substrate for the presystemic metabolising enzyme (even though the functional group originally attacked is not directly 'masked') 
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4.3 Prolongation of Drug Action 
For drugs rapidly cleared from the body, fre-
quent dosing with conventional dosage forms is re-
quired to maintain adequate plasma concentra-
tions of the particular drug. This frequent dosing 
of short half-life drugs results in sharp peak-valley 
plasma concentration-time profiles, and conse-
quently patient compliance is often poor. Sus-
tained or prolonged release drug products will often 
overcome such problems. Traditional formulation 
approaches are often quite successful but the com-
bination of a prodrug and a suitable delivery sys-
tem may allow for the sustained release of drugs 
for which a pure formulation approach may not 
work. 
Sinkula (1978) has summarised the ways in 
which alterations in the physicochemical proper-
ties of a drug, in the form of a prodrug, can be used 
to prolong or control drug action. They include al-
terations in: 
1. The degree and rate of absorption 
2. The rate and extent of conversion of the pro-
drug to the active species 
3. The rate and extent of protein or tissue binding 
4. The degree of tissue or organ localisation, dis-
tribution and subsequent release from such sites. 
The development of prodrugs for the prolong-
ation of therapeutic action has generally been 
avoided due to the inability to rationally predict 
the effect of the prodrug structural modification on 
the resulting pharmacokinetics. Future research will 
no doubt attempt to 'match' the delivery system 
with the drug or, if not possible, a prodrug to pro-
long drug action. The one area that has had some 
qualitative and predictive successes has been in the 
area of hormonal steroid and depot antipsychotic 
drug injections. 
4.3.1 Testosterone 
Lipophilic prodrugs of testosterone such as its 
17-propionate, 17-phenylacetate, and 17-cypionate 
esters are administered in an oil vehicle by deep 
intramuscular injection. 
It is generally accepted that these esters are 
slowly released from the intramuscular site after 
which they are stored in fat depots and ultimately 
cleaved to testosterone. For a detailed discussion 
of the release mechanisms, see Alibrandi et al. 
(1960), James et al (1969), Tanaka et a l (1974) 
and Sinkula (1977). 
4.3.2 Depot Antipsychotic Drugs 
This same technology has been applied to vari-
ous antipsychotic drugs. Prolongation of antipsy-
chotic action is particularly desirable with drugs 
used for the long term control of schizophrenic 
patients. The depot forms of fluphenazine are its 
enanthate (heptanoate) and decanoate esters. These 
esters have greater lipophilicity than the parent 
compound, and when administered in sterile se-
same oil, intramuscular injections exhibit a much 
longer duration of action than fluphenazine hydro-
chloride (fig. 7). It is worth mentioning that this 
type of prodrug approach has its clinical dangers. 
Once injected it is difficult to halt therapy if the 
patient experiences an adverse reaction to the drug. 
Unlike an implant that can be surgically removed 
or a transdermal patch that can be easily peeled 
off, once a deep intramuscular injection is given, 
if an adverse reaction occurs it probably can only 
be treated symptomatically. 
Other examples of prolonged prodrug forms of 
antipsychotic agents have been reviewed by Vil-
leneuve et al. (1972), Yale (1977, 1978), and Jor-
gensen (1978). 
4.3.3 Other Drugs 
Drug classes as different and diverse as /J-lactam 
antibiotics, antimalarials and hypoglycaemic agents 
have been studied with a view to increasing their 
duration of action. Success is not always forthcom-
ing because of the lack of predictive relationships 
between the structural modifications and the dur-
ation of action. 
Realistically, neither the prodrug nor delivery 
system approach may be sufficient on their own to 
prolong the action of a drug, e.g. systems like the 
Orose® osmotic delivery system are ideally suited 
to the delivery of water-soluble salts (Theeuwes, 
1975); therefore, a drug without sufficient aqueous 
solubility could not be used, or is less likely to be 
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F i g . 7 . Ruphenazine hydrochloride and its esters used for depot injections. 
used in such a system. The preparation of a pro-
drug with the ideal solubility properties may allow 
the use of such a sophisticated delivery system. It 
is thus likely that future drug products designed for 
prolonged action may well be suitably matched 
prodrug/delivery system combinations. 
4.4 Reduction in Toxicity 
One of the desired properties of all therapeuti-
cally active agents is that they have negligible or 
no toxicity associated with their clinical use. While 
it would be indeed naive to believe that toxico-
logical problems could be solved by prodrug form-
ulations, sufficient examples of a reduction in tox-
icity due to prodrug administration exist so as to 
provide an impetus for this exciting, albeit diffi-
cult, area of prodrug research. 
4.4.1 Aspirin and Sulindac 
As discussed earlier, aspirin can be considered 
a less corrosive prodrug form of salicylic acid. Sim-
ilarly, sulindac, also mentioned earlier, is a pro-
drug of the corresponding sulphide. Sulindac itself, 
as the sulphoxide form of the active sulphide 
moiety, has little or no pharmacological activity 
but is much more water soluble. The advantages 
of the higher water solubility as it relates to more 
efficient gastrointestinal absorption are discussed 
in section 3.3.3. Following its absorption as the in-
active sulphoxide, sulindac is reversibly reduced to 
the sulphide and a sulphoxide/sulphide equilib-
rium is established (fig. 3); the drug is also irrev-
ersibly oxidised to the inactive sulphone. T h e over-
all disposition of sulindac is complex and the 
subject of extensive research (Duggan, 1981; Dug-
gan et al., 1977, 1980; Dobrinska et al., 1983; Shen 
and Winter, 1977). Since the anti-inflammatory ac-
tivity and gastrointestinal intolerance of m a n y anti-
inflammatory drugs seem to be mediated by their 
inhibition of prostaglandin synthetase (Vane, 1974) 
and the ingested sulphoxide has little or no such 
activity, exposure of the gastrointestinal mucosa to 
the active substance is minimised. This m a y ac-
count for the reduced local gastrointestinal irrita-
tion caused by sulindac in comparison with certain 
other anti-inflammatory drugs such as aspirin, 
though such side effects are by no means absent. 
In addition, the active sulphide metaboli te of 
sulindac has a longer elimination half-life t han su-
lindac (16 vs 7 hours) and due to the bioequi l i -
brium between the two, a prolonged dura t ion of 
action enabling twice daily dosing is seen. More -
over, sulindac, like many large molecular weight 
anionic drugs, undergoes enterohepatic recircula-
tion mainly as either the unchanged prodrug or a s 
a glucuronide conjugate. The latter may b e cleaved 
in the intestine to liberate free sulindac, wh ich can 
again be absorbed into the general circulation. 
Sulindac is an excellent example of a clinically 
relevant prodrug with decreased toxicity a n d bet ter 
absorption characteristics than its active drug , a n d 
R = - H (as hydrochloride) 
R s - COC 6 H 1 3 F-enanthate 
R = - COC 9 H 1 9 F-decanoate 
Duration of action 
after IM injection 
6-8 hours 
2 weeks 
4 weeks 
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with a longer duration of action due to the con-
version kinetics between the sulphoxide and sul-
phide as well as the enterohepatic recycling. 
4.5 Achieving Site-Specific Drug Delivery 
The targeting of drugs for certain tissues, sites, 
enzymes, etc., represents a major portion of drug-
related research throughout the world. The use of 
prodrugs to achieve site specificity is one approach 
being actively pursued. This approach, along with 
others (Bundgaard et al., 1982; Gregoriadis, 1977, 
1979; Juliano, 1980), holds the hope for achieving 
very precise and direct effects at the 'site of action' 
without subjecting the rest of the body to signifi-
cant levels of the active agent. The hope is that 
effective therapy with minimal toxicity will be 
achieved. 
Recently, Stella and Himmelstein (1980, 1982) 
realistically evaluated the potential of achieving site-
specific delivery of drugs by using the prodrug ap-
proach. Using a hybrid physiological/classic phar-
macokinetic model, they tested various hypotheses 
which had been proposed to achieve site-specific 
delivery of drugs via prodrugs. They concluded that 
at least 3 factors had to be optimised: 
1. The prodrug must be readily transported to the 
site of action and uptake to the site must be 
rapid, and essentially perfusion rate-limited 
2. Once at the site, the prodrug must be selectively 
cleaved to the active drug relative to its con-
version at other sites. Perhaps as important, it 
must be selectively cleaved relative to cleavage 
in more highly perfused tissues such as the liver, 
kidney, etc. 
3. The active drug once selectively generated at the 
site of action must be somewhat retained by the 
tissue. 
Prior to 1980, only the first two points had gen-
erally been addressed. For example, selective up-
take into tumour cells had generally been unsuc-
cessful via prodrugs because they are relatively 
poorly perfused tissues compared with other or-
gans (Gray et al., 1953) like the liver, and many of 
the enzymes such as phosphatases that are elevated 
in tumours are not accessible to phosphate pro-
drugs, i.e. the phosphate prodrugs are too polar to 
enter the tumour cells. The last point (site reten-
tion) has not generally been recognised as being 
important, but is probably the basis for most of the 
failures, considering that most researchers have 
tried to selectively deliver currently known active 
drugs. For these drugs to be active they must be 
readily accessible to the site of action. Therefore, 
if they can reach the site of action, they will also 
readily equilibrate with other tissues. If these drugs, 
as prodrugs, are selectively delivered to the site of 
action, chances are that only a momentary burst 
of drug activity at the site will be seen (Stella and 
Himmelstein, 1980) before the drug rapidly equi-
librates with the rest of the body. Therefore the 
drugs which are most likely to be selectively deliv-
ered to target sites via prodrugs are likely to be 
agents that are as yet still under development, and 
for which the prodrug approach to selective deliv-
ery will be an integral part of a basic drug design 
programme. 
This is not to say that site-specific delivery is 
not desirable or attainable with all current drugs. 
There are some very important recent examples in 
the literature where the efficacy of a drug has been 
improved due to selective delivery. Some of the 
better examples involve the local delivery of drugs. 
Drugs destined for delivery to the skin, eye or ex-
ternal tissue can be substantially improved if a pro-
drug is designed which readily penetrates the rate-
limiting barrier to the tissue and is rapidly cleaved 
to the active drug. Site retention here is not quite 
as important because many of these tissues are not 
highly perfused such that drug turnover from these 
tissues is reasonably slow. 
4.5.1 Dipivefrin 
Locally administered solutions of adrenaline 
(epinephrine) have long been used for the treat-
ment of glaucoma, although both local ocular and 
systemically based side effects often occur. The pi-
valic acid ester prodrug of adrenaline, dipivefrin 
(dipivaloyladrenaline), is a therapeutically more ef-
ficacious agent than adrenaline itself (Anderson et 
a l , 1980; Mandell et a l , 1978; MeClure, 1975) [fig. 
8]. This ester is approximately 100 times more ac-
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R = -H Adrenaline 
R = -COC(CH3)3 Dipivefrin (dipivaloyladrenaltne) 
F i g . 8. Structural formulae of adrenaline (epinephrine) and its 
pivalic acid ester prodrug, dipivefrin (dipivaloyiadrenaline). 
tive than adrenaline in lowering intraocular pres-
sure due to glaucoma. The greater potency results 
from more efficient corneal transport, followed by 
rapid cleavage of the ester in its passage through 
the corneal tissue releasing adrenaline to the 
aqueous humour fluid (Anderson et al, 1980). In 
addition, because lower doses of the ester can be 
used, untoward cardiac side effects due to adren-
aline absorption from the tear duct overflow are 
diminished and the accumulation of melanin de-
posits in the eye are not seen. 
4.5.2 Pro-2-PAM 
Systemic site-specific delivery is probably one 
of the ultimate goals in drug delivery. This process 
is infinitely more complex than local site-specific 
delivery because the drug (or prodrug) must be 
transported into and via the blood through a variety 
of complex barriers before reaching the target or-
gan. There have been a number of recent attempts 
at promoting systemic site specificity via increased 
permeability of a drug to a particular organ by pro-
drug modifications. Bodor et al. (1975, 1976) and 
Shek et al. (1976a,b) were able to increase the brain 
concentrations of the highly polar quaternary am-
monium anticholinesterase inhibitor, 2-PAM 
(pralidoxime), by administering its dihydro-pro-
drug, pro-2-PAM. Pro-2-PAM rapidly reverts to 2-
PAM by an in vivo oxidative mechanism. The suc-
cess of pro-2-PAM is due to its increased perme-
ability through the blood-brain barrier and to the 
presence of enzymes in the brain capable of con-
verting pro-2-PAM to 2-PAM. Although brain con-
centrations of 2-PAM were significantly increased 
by pro-2-PAM administration relative to 2-PAM 
itself, the majority of the administered dose of pro-
2-PAM was converted to 2-PAM in tissues and or-
gans other than the brain. If the brain was selec-
tively able to convert pro-2-PAM to 2-PAM, true 
site-selective delivery may have been achievable in 
this case. 
Similar studies for the delivery of other aro-
matic quaternary ammonium compounds have re-
cently been published (Bodor and Brewster, 1983; 
Repta et al., 1982). 
4.5.3 y-Glutamyl-Dopamine and y-Glutamyl-
L~Dopa 
A number of studies that have attempted to 
utilise the high levels of 7-glutamyl transpeptidase 
in the kidney have arrived at some interesting find-
ings. The selective delivery of dopamine, useful in 
the treatment of shock (due to its vasodilatory ac-
tion on the kidney), has been achieved by the pro-
drug 7-glutamyl-dopamine (Kyncl et al , 1979) and 
7-glutamyl-L-dopa (Wilk et al., 1978). Here the 
polar prodrugs were able to reach the highly per-
fused kidney where selective cleavage by 7-gluta-
myl transpeptidase released the polar dopamine, 
resulting in its selective delivery to the kidney. 
At present, systemic site-specific delivery by 
prodrugs is applicable to a small number of cur-
rently useful therapeutic agents. However, it is en-
visaged that this approach will become more suc-
cessful as it is applied to new chemical entities 
whose potential activity is determined by their ac-
tion in an in vitro biochemical screen, but whose 
physicochemical properties are such that delivery 
to the in vivo target site is seen as a problem. Here 
the statement by Higuchi (personal communica-
tion) that 'drugs will have to be designed with de-
livery components in mind' is most pertinent. 
In the next decade the term prodrug may dis-
appear from common usage as the approach will 
become an integral part of basic drug design and 
not necessarily as a hindsighted approach to the 
solution of problems associated with older drugs. 
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